These findings, together with a significant correlation between high TBX2 expression levels in primary tumors and reduced metastasis-free survival of breast cancer patients, suggest that TBX2 may be an attractive new target for anti-metastatic cancer therapies. The gene discussed is TBX2; the disease is metastatic malignant neoplasm.